- Home
- Who we are
- Read, watch, listen
- Pharmacy
- Home Delivery
- Specialty Pharmacy
- Specialty Pharmacy - Patients
- Care Specialists Program
- Education Center
- Hypercholesterolemia
- Solid organ transplant
- Asthma
- Cystic fibrosis
- Hemophilia
- Hepatitis C
- Human Immunodeficiency Virus (HIV)
- Inflammatory bowel disease
- Osteoporosis
- Multiple Sclerosis
- Oncology (cancer)
- Psoriasis and psoriatic arthritis
- Rheumatoid arthritis
- Rights and responsibilities
- Overcome medicine challenges
- Specialty Pharmacy - Providers
- Patient Forms
- Careers
- Benefits
- Hub + Home
- Medication Therapy Management Internship
- Managed Care Residency Program
- Application Process
- Contact Us
- Newsroom Custom Content
- Prime Careers Spotlight
- Prime Careers Spotlight: September 2024
- Prime Careers Spotlight: October 2024
- Prime Careers Spotlight: November 2024
- Prime Careers Spotlight: April 2025
- Prime Careers Spotlight: May 2025
- Prime Careers Spotlight: June 2025
- Prime Careers Spotlight: July 2025
- Prime Careers Spotlight: August 2025
- Prime Careers Spotlight: September 2025
- Prime Careers Spotlight: October 2025
- Prime Careers Spotlight: November 2025
- Prime Careers Spotlight: December 2025
- Prime Careers Spotlight: January 2026
- Prime Careers Spotlight: February 2026
- Publications
- Quarterly Pipeline
- 2024-2025
- Quarterly Drug Pipeline: July 2024
- Quarterly Drug Pipeline: April 2024
- Quarterly Drug Pipeline: January 2024
- Quarterly Drug Pipeline Template 2.0
- Quarterly Drug Pipeline: October 2024
- Quarterly Drug Pipeline: January 2025
- Quarterly Drug Pipeline: April 2025
- Quarterly Drug Pipeline: July 2025
- Quarterly Drug Pipeline: October 2025
- Quarterly Drug Pipeline: January 2026
- Clinical Highlights
- Clinical Highlights: September 2024
- Clinical Highlights: October 2024
- Clinical Highlights: November 2024
- Clinical Highlights: December 2024
- Clinical Highlights: January 2025
- Clinical Highlights: February 2025
- Clinical Highlights: March 2025
- Clinical Highlights: April 2025
- Drug Approvals
- Drug Approvals Monthly Update: August 2024
- Drug Approvals Monthly Update: June 2024
- Drug Approvals Monthly Update: May 2024
- Drug Approvals Monthly Update: April 2024
- Drug Approvals Monthly Update: March 2024
- Drug Approvals Monthly Update: February 2024
- Drug Approvals Monthly Update: January 2024
- Drug Approvals Quarterly Update
- Drug Approvals Monthly Update: September 2024
- Drug Approvals: October 2024
- Drug Approvals: November 2024
- Drug Approvals: December 2024
- Drug Approvals: January 2025
- Drug Approvals: July 2024
- Drug Approvals: February 2025
- Drug Approvals: March 2025
- Drug Approvals: April 2025
- Quarterly Drug Approvals
- 2024-2025
- Quarterly Drug Approvals: October 2024
- Quarterly Drug Approvals: January 2025
- Quarterly Drug Approvals: April 2025
- Quarterly Drug Approvals: July 2025
- Quarterly Drug Approvals: October 2025
- Quarterly Drug Approvals: January 2026
- High Cost Therapy Profile
- 2024-2025
- High-Cost Therapy Profile: August 2024
- High-Cost Therapy Profile: June 2024
- High-Cost Therapy Profile: May
- High-Cost Therapy Profile: April
- High-Cost Therapy Profile: March
- High-Cost Therapy Profile: February
- High-Cost Therapy Profile: January
- High-Cost Therapy Profile: September 2024
- HIGH COST THERAPY PROFILE: OCT 2024
- High Cost Therapy Profile: November 2024
- High Cost Therapy Profile: December 2024
- High Cost Therapy Profile: January 2025
- High Cost Therapy Profile: February 2025
- High-Cost Therapy Profile: March 2025
- High Cost Therapy Profile: April 2025
- High-Cost Therapy Profile: May 2025
- High-Cost Therapy Profile: June 2025
- High-Cost Therapy Profile: July 2025
- High-Cost Therapy Profile: August 2025
- High-Cost Therapy Profile: September 2025
- High-Cost Therapy Profile: October 2025
- High-Cost Therapy Profile: November 2025
- High-Cost Therapy Profile: December 2025
- High-Cost Therapy Profile: January 2026
- High-Cost Therapy Profile: February 2026
- Oncology Insights
- 2024-2025
- Oncology Insights: Transformative treatment for small cell lung cancer
- Oncology Insights: First-in-class bladder cancer therapy and the Bacillus Calmette-Guérin (BCG) shortage
- Oncology Insights: October 2024
- Oncology Insights: December 2024
- Oncology Insights: 2024 Rewind
- Oncology Insights: February 2025
- Oncology Insights: March 2025
- Oncology Insights: April 2025
- Oncology Insights: May 2025
- Oncology Insights: June 2025
- Oncology Insights: July 2025
- Oncology Insights: August 2025
- Oncology Insights: September 2025
- Oncology Insights: October 2025
- Oncology Insights: November 2025
- Oncology Insights: December 2025
- Oncology Insights: January 2026
- Oncology Insights: February 2026
- FDA Decisions Expected
- 2024-2025
- FDA Decisions Expected: October 2024
- FDA Decisions Expected November 2024
- FDA Decisions Expected: December 2024
- FDA Decisions Expected: January 2025
- FDA Decisions Expected: February 2025
- FDA Decisions Expected: March 2025
- FDA Decisions Expected: April 2025
- FDA Decisions Expected: May 2025
- FDA Decisions Expected: June 2025
- FDA Decisions Expected: July 2025
- FDA Decisions Expected: August 2025
- FDA Decisions Expected: September2025
- FDA Decisions Expected: October 2025
- FDA Decisions Expected: November 2025
- FDA Decisions Expected: December 2025
- FDA Decisions Expected: January 2026
- FDA Decisions Expected: February 2026
- FDA Decisions Expected: March 2026
- Expert Clinical Network Insights
- 2024-2025
- Expert Clinical Network Insights: June 2024
- Expert Clinical Network Insights: April 2024
- Expert Clinical Network Insights: October 2024
- Expert Clinical Network Insights: December 2024
- Expert Clinical Network Insights: March 2025
- Expert Clinical Network Insights: August 2025
- Expert Clinical Network Insights: September 2025
- Expert Clinical Network Insights: December 2025
- Expert Clinical Network Insights: January 2026
- Prime Therapeutics Reports
- Fall 2024 Prime Therapeutics Report
- Spring 2024 Prime Therapeutics Report
- Summer 2024 Prime Therapeutics Report
- Spring 2025 Prime Therapeutics Report
- Summer 2025 Prime Therapeutics Report
- Fall 2025 Prime Therapeutics Report
- GLP-1
- 2024-2025
- GLP-1 Pipeline Update: November 2024
- GLP-1 Pipeline Update: November 2025
- The evolution of GLP-1s
- GLP-1 Pipeline Update: February 2025
- GLP-1 Pipeline Update: May 2025
- GLP-1 Pipeline Update: August 2025
- GLP-1 Pipeline Update: February 2026
- Clinical Insights
- 2022 Clinical Insights: Therapeutic Psychedlics: An emerging frontier in mental health
- 2022 Clinical Insights: Virtual reality: An emerging paradigm in healthcare
- Summer 2025 Issue: Clinical Insights – MASH
- Trending Topics & Drug Approvals
- 2024-2025
- Trending Topics & Drug Approvals: May 2025
- Trending Topics & Drug Approvals: June 2025
- Trending Topics & Drug Approvals: July 2025
- Trending Topics & Drug Approvals: August 2025
- Trending Topics & Drug Approvals: September 2025
- Trending Topics & Drug Approvals: November 2025
- Trending Topics & Drug Approvals: December 2025
- Trending Topics & Drug Approvals: January 2026
- Cell & Gene Pipeline Outlook
- Clinical News
- Clinical News
- Clinical News: August 2024
- Clinical News: June 2024
- Clinical News: May 2024
- Clinical News: April 2024
- Employer Market Insight Reports
- Pharmacy Trend Reports
- Medicaid Pharmacy Trend Reports
- 2024 Medical Pharmacy Trend Report
- 2025 Medical Pharmacy Trend Report
- Weight management: A holistic journey
- Climate change: An imprint on health
- Virtual reality: An emerging paradigm in health care
- Research
- AMCP Nexus 2025 research posters
- AMCP Nexus 2024 Research Posters
- 2024 AMCP Annual Meeting Research Posters
- Media
- Compliance / Legal
- Home
- Who we are
- Read, watch, listen
- Pharmacy
- Home Delivery
- Specialty Pharmacy
- Specialty Pharmacy - Patients
- Care Specialists Program
- Education Center
- Hypercholesterolemia
- Solid organ transplant
- Asthma
- Cystic fibrosis
- Hemophilia
- Hepatitis C
- Human Immunodeficiency Virus (HIV)
- Inflammatory bowel disease
- Osteoporosis
- Multiple Sclerosis
- Oncology (cancer)
- Psoriasis and psoriatic arthritis
- Rheumatoid arthritis
- Rights and responsibilities
- Overcome medicine challenges
- Specialty Pharmacy - Providers
- Patient Forms
- Careers
- Benefits
- Hub + Home
- Medication Therapy Management Internship
- Managed Care Residency Program
- Application Process
- Contact Us
- Newsroom Custom Content
- Prime Careers Spotlight
- Prime Careers Spotlight: September 2024
- Prime Careers Spotlight: October 2024
- Prime Careers Spotlight: November 2024
- Prime Careers Spotlight: April 2025
- Prime Careers Spotlight: May 2025
- Prime Careers Spotlight: June 2025
- Prime Careers Spotlight: July 2025
- Prime Careers Spotlight: August 2025
- Prime Careers Spotlight: September 2025
- Prime Careers Spotlight: October 2025
- Prime Careers Spotlight: November 2025
- Prime Careers Spotlight: December 2025
- Prime Careers Spotlight: January 2026
- Prime Careers Spotlight: February 2026
- Publications
- Quarterly Pipeline
- 2024-2025
- Quarterly Drug Pipeline: July 2024
- Quarterly Drug Pipeline: April 2024
- Quarterly Drug Pipeline: January 2024
- Quarterly Drug Pipeline Template 2.0
- Quarterly Drug Pipeline: October 2024
- Quarterly Drug Pipeline: January 2025
- Quarterly Drug Pipeline: April 2025
- Quarterly Drug Pipeline: July 2025
- Quarterly Drug Pipeline: October 2025
- Quarterly Drug Pipeline: January 2026
- Clinical Highlights
- Clinical Highlights: September 2024
- Clinical Highlights: October 2024
- Clinical Highlights: November 2024
- Clinical Highlights: December 2024
- Clinical Highlights: January 2025
- Clinical Highlights: February 2025
- Clinical Highlights: March 2025
- Clinical Highlights: April 2025
- Drug Approvals
- Drug Approvals Monthly Update: August 2024
- Drug Approvals Monthly Update: June 2024
- Drug Approvals Monthly Update: May 2024
- Drug Approvals Monthly Update: April 2024
- Drug Approvals Monthly Update: March 2024
- Drug Approvals Monthly Update: February 2024
- Drug Approvals Monthly Update: January 2024
- Drug Approvals Quarterly Update
- Drug Approvals Monthly Update: September 2024
- Drug Approvals: October 2024
- Drug Approvals: November 2024
- Drug Approvals: December 2024
- Drug Approvals: January 2025
- Drug Approvals: July 2024
- Drug Approvals: February 2025
- Drug Approvals: March 2025
- Drug Approvals: April 2025
- Quarterly Drug Approvals
- 2024-2025
- Quarterly Drug Approvals: October 2024
- Quarterly Drug Approvals: January 2025
- Quarterly Drug Approvals: April 2025
- Quarterly Drug Approvals: July 2025
- Quarterly Drug Approvals: October 2025
- Quarterly Drug Approvals: January 2026
- High Cost Therapy Profile
- 2024-2025
- High-Cost Therapy Profile: August 2024
- High-Cost Therapy Profile: June 2024
- High-Cost Therapy Profile: May
- High-Cost Therapy Profile: April
- High-Cost Therapy Profile: March
- High-Cost Therapy Profile: February
- High-Cost Therapy Profile: January
- High-Cost Therapy Profile: September 2024
- HIGH COST THERAPY PROFILE: OCT 2024
- High Cost Therapy Profile: November 2024
- High Cost Therapy Profile: December 2024
- High Cost Therapy Profile: January 2025
- High Cost Therapy Profile: February 2025
- High-Cost Therapy Profile: March 2025
- High Cost Therapy Profile: April 2025
- High-Cost Therapy Profile: May 2025
- High-Cost Therapy Profile: June 2025
- High-Cost Therapy Profile: July 2025
- High-Cost Therapy Profile: August 2025
- High-Cost Therapy Profile: September 2025
- High-Cost Therapy Profile: October 2025
- High-Cost Therapy Profile: November 2025
- High-Cost Therapy Profile: December 2025
- High-Cost Therapy Profile: January 2026
- High-Cost Therapy Profile: February 2026
- Oncology Insights
- 2024-2025
- Oncology Insights: Transformative treatment for small cell lung cancer
- Oncology Insights: First-in-class bladder cancer therapy and the Bacillus Calmette-Guérin (BCG) shortage
- Oncology Insights: October 2024
- Oncology Insights: December 2024
- Oncology Insights: 2024 Rewind
- Oncology Insights: February 2025
- Oncology Insights: March 2025
- Oncology Insights: April 2025
- Oncology Insights: May 2025
- Oncology Insights: June 2025
- Oncology Insights: July 2025
- Oncology Insights: August 2025
- Oncology Insights: September 2025
- Oncology Insights: October 2025
- Oncology Insights: November 2025
- Oncology Insights: December 2025
- Oncology Insights: January 2026
- Oncology Insights: February 2026
- FDA Decisions Expected
- 2024-2025
- FDA Decisions Expected: October 2024
- FDA Decisions Expected November 2024
- FDA Decisions Expected: December 2024
- FDA Decisions Expected: January 2025
- FDA Decisions Expected: February 2025
- FDA Decisions Expected: March 2025
- FDA Decisions Expected: April 2025
- FDA Decisions Expected: May 2025
- FDA Decisions Expected: June 2025
- FDA Decisions Expected: July 2025
- FDA Decisions Expected: August 2025
- FDA Decisions Expected: September2025
- FDA Decisions Expected: October 2025
- FDA Decisions Expected: November 2025
- FDA Decisions Expected: December 2025
- FDA Decisions Expected: January 2026
- FDA Decisions Expected: February 2026
- FDA Decisions Expected: March 2026
- Expert Clinical Network Insights
- 2024-2025
- Expert Clinical Network Insights: June 2024
- Expert Clinical Network Insights: April 2024
- Expert Clinical Network Insights: October 2024
- Expert Clinical Network Insights: December 2024
- Expert Clinical Network Insights: March 2025
- Expert Clinical Network Insights: August 2025
- Expert Clinical Network Insights: September 2025
- Expert Clinical Network Insights: December 2025
- Expert Clinical Network Insights: January 2026
- Prime Therapeutics Reports
- Fall 2024 Prime Therapeutics Report
- Spring 2024 Prime Therapeutics Report
- Summer 2024 Prime Therapeutics Report
- Spring 2025 Prime Therapeutics Report
- Summer 2025 Prime Therapeutics Report
- Fall 2025 Prime Therapeutics Report
- GLP-1
- 2024-2025
- GLP-1 Pipeline Update: November 2024
- GLP-1 Pipeline Update: November 2025
- The evolution of GLP-1s
- GLP-1 Pipeline Update: February 2025
- GLP-1 Pipeline Update: May 2025
- GLP-1 Pipeline Update: August 2025
- GLP-1 Pipeline Update: February 2026
- Clinical Insights
- 2022 Clinical Insights: Therapeutic Psychedlics: An emerging frontier in mental health
- 2022 Clinical Insights: Virtual reality: An emerging paradigm in healthcare
- Summer 2025 Issue: Clinical Insights – MASH
- Trending Topics & Drug Approvals
- 2024-2025
- Trending Topics & Drug Approvals: May 2025
- Trending Topics & Drug Approvals: June 2025
- Trending Topics & Drug Approvals: July 2025
- Trending Topics & Drug Approvals: August 2025
- Trending Topics & Drug Approvals: September 2025
- Trending Topics & Drug Approvals: November 2025
- Trending Topics & Drug Approvals: December 2025
- Trending Topics & Drug Approvals: January 2026
- Cell & Gene Pipeline Outlook
- Clinical News
- Clinical News
- Clinical News: August 2024
- Clinical News: June 2024
- Clinical News: May 2024
- Clinical News: April 2024
- Employer Market Insight Reports
- Pharmacy Trend Reports
- Medicaid Pharmacy Trend Reports
- 2024 Medical Pharmacy Trend Report
- 2025 Medical Pharmacy Trend Report
- Weight management: A holistic journey
- Climate change: An imprint on health
- Virtual reality: An emerging paradigm in health care
- Research
- AMCP Nexus 2025 research posters
- AMCP Nexus 2024 Research Posters
- 2024 AMCP Annual Meeting Research Posters
- Media
- Compliance / Legal
Support your members with hemophilia
Learn more about hemophilia
Hemophilia is a rare bleeding disorder that happens when the blood does not clot normally due to missing or low levels of proteins known as clotting factors. This is an X-linked recessive disorder. This means both parents need to be carriers for their child to have hemophilia. Women are most often carriers, and hemophilia occurs much more frequently in men than in women. Hemophilia occurs in about 1 in 5,600 live male births, and between 30,000–33,000 men in United States have hemophilia.1
14
Hemophilia is the 14th most expensive drug category based on Prime’s combined commercial medical and pharmacy claims data.2
See how Prime can help
Advances in treatment have improved quality and length of life for those with hemophilia, but hemophilia factor prophylaxis treatment can be costly — frequently more than $600,000 per year.3 As with drugs for many chronic conditions, members can find it challenging to follow treatment plans. They may also face a lack of individualized treatment and fragmentation of care between treatment centers and pharmacies. That’s where Prime comes in, delivering:
Proactive education
Prime educates providers, pharmacies and hemophilia patient advocacy groups on your program policies and goals before we implement our hemophilia solutions.
Quality assurance
We use your data to determine utilization patterns, outlier members, treatment facilities, prescribing habits and cost compared to national and regional benchmarks.
Clinical rigor
Manage your benefits and data through our utilization management (UM) reviews, which provide key clinical info and optimize factor dosing in line with pharmacokinetic (PK) testing.
Choose what works best for you and your members
Footnotes
*All brand names are property of their respective owners.
**The programs listed are not available to all clients. Please check with your representative if you are interested in learning more.
1 Soucie, J. M., Miller, C. H., Dupervil, B., Le, B., & Buckner, T. W. (2020). Occurrence rates of haemophilia among males in the United States based on surveillance conducted in specialized haemophilia treatment centres. Haemophilia, 26(3), 487–493. https://doi.org/10.1111/hae.13998
2 Internal analysis, 2024
3 Patient Out-of-Pocket Expenses. (n.d.). National Bleeding Disorders Foundation. https://www.bleeding.org/advocacy/state-priorities/patient-out-of-pocket-expenses
4 Internal analysis, 2017-2024